AAAAAA

   
Results: 1-25 | 26-32 |
Results: 26-32/32
PHASE-I STUDY OF RP 49532A, A NEW PROTEIN-SYNTHESIS INHIBITOR, IN PATIENTS WITH ADVANCED REFRACTORY SOLID TUMORS
Authors: CATIMEL G COQUARD R GUASTALLA JP MERROUCHE Y LEBAIL N ALAKL MK DUMORTIER A FOY M CLAVEL M
Citation: G. Catimel et al., PHASE-I STUDY OF RP 49532A, A NEW PROTEIN-SYNTHESIS INHIBITOR, IN PATIENTS WITH ADVANCED REFRACTORY SOLID TUMORS, Cancer chemotherapy and pharmacology, 35(3), 1995, pp. 246-248
PHASE-II TRIAL OF FLUTAMIDE IN ADVANCED OVARIAN-CANCER - AN EORTC GYNECOLOGICAL CANCER COOPERATIVE GROUP-STUDY
Authors: TUMOLO S RAO BR VANDERBURG ME GUASTALLA JP RENARD J VERMORKEN JB
Citation: S. Tumolo et al., PHASE-II TRIAL OF FLUTAMIDE IN ADVANCED OVARIAN-CANCER - AN EORTC GYNECOLOGICAL CANCER COOPERATIVE GROUP-STUDY, European journal of cancer, 30A(7), 1994, pp. 911-914
2ND-LINE CHEMOTHERAPY IN EPITHELIAL OVARIAN-CARCINOMA - PLATINUM AGAIN - TAXANES - HOW TO CHOOSE
Authors: GUASTALLA JP
Citation: Jp. Guastalla, 2ND-LINE CHEMOTHERAPY IN EPITHELIAL OVARIAN-CARCINOMA - PLATINUM AGAIN - TAXANES - HOW TO CHOOSE, European journal of cancer, 30A(12), 1994, pp. 1739-1741
PHASE-II TRIAL FOR INTRAPERITONEAL CISPLATIN PLUS INTRAVENOUS-SODIUM THIOSULFATE IN ADVANCED OVARIAN-CARCINOMA PATIENTS WITH MINIMAL RESIDUAL DISEASE AFTER CISPLATIN-BASED CHEMOTHERAPY - A PHASE-II STUDY OF THE EORTC GYNECOLOGICAL CANCER COOPERATIVE GROUP
Authors: GUASTALLA JP VERMORKEN JB WILS JA GEORGE M SCOTTO V NOOIJ M HUINNINK WWT DALESIO O RENARD J
Citation: Jp. Guastalla et al., PHASE-II TRIAL FOR INTRAPERITONEAL CISPLATIN PLUS INTRAVENOUS-SODIUM THIOSULFATE IN ADVANCED OVARIAN-CARCINOMA PATIENTS WITH MINIMAL RESIDUAL DISEASE AFTER CISPLATIN-BASED CHEMOTHERAPY - A PHASE-II STUDY OF THE EORTC GYNECOLOGICAL CANCER COOPERATIVE GROUP, European journal of cancer, 30A(1), 1994, pp. 45-49
A PHASE-I ANTIEMETIC STUDY OF MDL-73,147EF, A NOVEL 5-HYDROXYTRYPTAMINE ANTAGONIST IN CANCER-PATIENTS RECEIVING EMETOGENIC CHEMOTHERAPY
Authors: MERROUCHE Y CATIMEL G REBATTU P DUMORTIER A GUASTALLA JP OGRADY P CLAVEL M
Citation: Y. Merrouche et al., A PHASE-I ANTIEMETIC STUDY OF MDL-73,147EF, A NOVEL 5-HYDROXYTRYPTAMINE ANTAGONIST IN CANCER-PATIENTS RECEIVING EMETOGENIC CHEMOTHERAPY, Annals of oncology, 5(6), 1994, pp. 549-551
PHASE-II TRIAL OF INTRAPERITONEAL CARBOPLATIN IN OVARIAN-CARCINOMA PATIENTS WITH MACROSCOPIC RESIDUAL DISEASE AT 2ND-LOOK LAPAROTOMY
Authors: GUASTALLA JP LHOMME C KERBRAT P MAYER F NAMER M GOUPIL P CHARROT P HERON JF CHAZARD M RICHARD I CHAUVIN F
Citation: Jp. Guastalla et al., PHASE-II TRIAL OF INTRAPERITONEAL CARBOPLATIN IN OVARIAN-CARCINOMA PATIENTS WITH MACROSCOPIC RESIDUAL DISEASE AT 2ND-LOOK LAPAROTOMY, Annals of oncology, 5(2), 1994, pp. 127-132
FAC (FLUOROURACIL, DOXORUBICIN, CYCLOPHOSPHAMIDE) AS 2ND LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC BREAST-CANCER PROGRESSING UNDER FEC (FLUOROURACIL, EPIRUBICIN, CYCLOPHOSPHAMIDE) CHEMOTHERAPY
Authors: CATIMEL G CHAUVIN F GUASTALLA JP REBATTU P BIRON P CLAVEL M
Citation: G. Catimel et al., FAC (FLUOROURACIL, DOXORUBICIN, CYCLOPHOSPHAMIDE) AS 2ND LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC BREAST-CANCER PROGRESSING UNDER FEC (FLUOROURACIL, EPIRUBICIN, CYCLOPHOSPHAMIDE) CHEMOTHERAPY, Annals of oncology, 5(1), 1994, pp. 95-97
Risultati: 1-25 | 26-32 |